Zantac 75 Acid Suppression "Remarkably Close" To Rx Strength - Ad
This article was originally published in The Tan Sheet
Executive Summary
The ability of Zantac 75 to suppress stomach acid is claimed to be almost comparable to that of prescription strength ranitidine 150 mg in an ad for Warner-Lambert's OTC H2 antagonist in the Sept. 1 issue of the Journal of the American Medical Association.
You may also be interested in...
Pepcid AC Label Directing Use 15 Minutes Before Eating Approved
New Pepcid AC dosing directions advising use 15 minutes before consumption of heartburn-inducing foods or beverages may help defend the product against comparative ads by other OTC H2 antagonists, also recently relabeled with similar dosing directions. J&J/Merck's efficacy supplement to its NDA for OTC famotidine 10 mg was approved by FDA Nov 9.
Zantac 75 EFFERdose approval dependent upon minor label changes.
ZANTAC 75 EFFERDOSE FIRST OTC EFFERVESCENT H2 ANTAGONIST to be approved by FDA. Glaxo Wellcome's NDA (20-745) for the effervescent tablet form of 75 mg ranitidine cleared the agency Feb. 26. Glaxo received an "approvable" letter for the effervescent dosage form of the heartburn remedy July 8 ("The Tan Sheet" July 28, 1997, p. 8). The NDA was filed in July 1996. Warner-Lambert markets Zantac 75 under a joint venture arrangement for Glaxo's Rx-to-OTC switch products.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC